Japan Earnings Highlights: New Products Win The Day For Top Pharma
This article was originally published in PharmAsia News
PharmAsia News brings highlights from Japan’s week of earnings presentations.
You may also be interested in...
The companies expect the demonstrated improvement in progression-free survival will be particularly compelling for urologists treating castrate-resistant prostate cancer in patients who have not started chemotherapy.
J&J’s canagliflozin is the first approval for a new pharmacologic approach to diabetes treatment, so FDA and the sponsor looked closely at the mechanism of action to identify safety questions – and to structure a clinical program that would provide data to answer them in the first review cycle.
The National Business Group on Health survey illustrates the continuing reimbursement challenges faced by the recently introduced obesity drugs Qsymia and Belviq.